camostat mesylate (Q23731028)
Jump to navigation
Jump to search
Indications
- candidate antiviral agent for treatment of COVID-19[1]
Dosage
- 100 mg PO BID used in children with hematuria & proteinuria
Mechanism of action
- appears to inbibit transmembrane serine protease TMPRSS2
Notes
- approved in Japan for chronic pancreatitis & postoperative reflux esophagitis
More general terms
References
- ↑ 1.0 1.1 Hoffmann M, Kleine-Weber H, Schroeder S SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Mar 4. pii: S0092-8674(20)30229-4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32142651
- ↑ Wikidata: camostat mesylate https://www.wikidata.org/wiki/Q23731028
- ↑ PubChem: 5284360
- ↑ Asami T, Tomisawa S, Uchiyama M. Effect of oral camostat mesilate on hematuria and/or proteinuria in children. Pediatr Nephrol 19, 313-316 2004 PMID: https://www.ncbi.nlm.nih.gov/pubmed/14740285 https://link.springer.com/article/10.1007%2Fs00467-003-1377-9
- ↑ Yamawaki H, Futagami S, Kaneko K et al Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. Digestion. 2019;99(4):283-292. Epub 2018 Nov 2. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30391941